United Therapeutics said its second Phase 3 idiopathic pulmonary fibrosis trial for Tyvaso (treprostinil) met endpoints, strengthening the case for regulatory momentum and a potential priority review for a supplemental NDA. The company also framed the result as building on the first Phase 3 study, with performance that could support a launch path into 2027. Tyvaso is delivered as a nebulized inhalation solution, and the update centers on efficacy measures including improvements in forced vital capacity. United also reported reduced risk of clinical worsening, with safety results characterized as well-tolerated. For pulmonary fibrosis drug developers, the update matters because it tightens competitive windows for next-line therapies and can affect payor and investigator expectations around how inhaled prostacyclin pathway drugs perform as combination and sequencing strategies evolve. Investors will watch how United translates Phase 3 results into the supplemental NDA package and whether regulators grant accelerated or priority review status for the label expansion.